Second clinical candidate from HUTCHMED’s next-generation ATTC platform —— Leveraging synergy through simultaneous inhibition of PAM pathway ...
Executives from ALX Oncology (NASDAQ:ALXO) outlined the company’s clinical and corporate priorities at a recent investor event, emphasizing a narrowed focus on two oncology assets: its lead CD47 ...
Detailed price information for Alx Oncology Holdings Inc (ALXO-Q) from The Globe and Mail including charting and trades.
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset ...
Signs Term Sheet To Acquire Two Clinical-Stage NSCLC Assets. Kairos Pharma (NYSE American: KAPA) announced it has signed a term sheet for a strategic asset acquisition from Celyn Therapeutics Inc., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results